Dr. Peter Houghton speaks to ecancer about the prospective validation of single mouse testing by the pediatric preclinical testing consortium; a study that was presented at ENA 2020 this year.
Dr. Houghton initially explains the rationale behind this study and talks about how it was tested that using a single mouse for studying drug efficacy in pediatric cancers can give the same results as using more mice.
He considers it to be a great scientific breakthrough that can change how pre-clinical testing is done currently. He then speaks of the key results obtained from this study and how they can impact the future.